<DOC>
	<DOCNO>NCT02827500</DOCNO>
	<brief_summary>The PRIME-HF study multi-center , patient-level , randomize , open-label study approximately 450 patient reduce ( left ventricular ejection fraction ) LVEF &lt; 35 % heart-rate &gt; 70 beat per minute ( bpm ) discharge hospital follow stabilization acute heart failure ( HF ) randomize treatment strategy predischarge initiation ivabradine usual care . All participant follow-up visit within 7-14 day hospital discharge . Heart rate systolic blood pressure assess clinical visit . For participant randomize predischarge initiation ivabradine ivabradine 5mg BID , heart rate may use adjust dose dose 2.5mg BID 7.5mg BID . For participant randomize usual care , ivabradine may initiate provider 's discretion . All participant second follow-up study visit 6 week ( 42 +/- 14 day ) post-discharge . Heart rate , systolic blood pressure quality life ( KCCQ PGA ) assess . For participant already take ivabradine either treatment group , heart rate may use adjust dose ivabradine . For participant yet receive ivabradine , may initiate provider 's discretion . All participant receive 90 ( +/-7 ) day post-discharge phone call site assess event status tolerability ivabradine . All participant final study visit 180 ( +/-14 ) day post-discharge . Heart rate , systolic blood pressure quality life ( Kansas City Cardiomyopathy Questionnaire Patient Global Assessment ) assess . The attend physician may initiate ivabradine per usual care clinical practice . The primary hypothesis PRIME-HF study , compare usual care , treatment strategy initiation ivabradine prior discharge hospitalization acute HF associate great proportion participant use ivabradine 180 day . Secondary objective assess impact predischarge initiation ivabradine : Heart Rate ( Percent change heart rate baseline 180 day Median heart rate 180 day ) Patient-Centered Outcomes ( Kansas City Cardiomyopathy Questionnaire ( KCCQ ) Patient Global Assessment ( PGA ) ) . Tertiary objective explore impact predischarge initiation ivabradine assessment evidence-based implementation ivabradine beta-blockers 180 day . Evaluations incorporate data base whether indication status retain whether ivabradine prescription provide . Tolerability ivabradine adverse event study follow-up .</brief_summary>
	<brief_title>Predischarge Initiation Ivabradine Management Heart Failure ( PRIME-HF )</brief_title>
	<detailed_description>- Purpose study The primary hypothesis PRIME-HF study , compare usual care , treatment strategy initiation ivabradine prior discharge hospitalization acute HF associate great proportion participant use ivabradine 180 day . Secondary objective assess impact predischarge initiation ivabradine : Heart Rate ( Percent change heart rate baseline 180 day Median heart rate 180 day ) Patient-Centered Outcomes ( Kansas City Cardiomyopathy Questionnaire ( KCCQ ) Patient Global Assessment ( PGA ) ) . Tertiary objective explore impact predischarge initiation ivabradine assessment evidence-based implementation ivabradine beta-blockers 180 day . Evaluations incorporate data base whether indication status retain whether ivabradine prescription provide . Tolerability ivabradine adverse event study follow-up . - Background &amp; significance Heart failure major public health issue . More 5 million Americans HF prevalence expect increase population age survival coronary , hypertensive , valvular heart disease improve . Data randomize clinical trial establish efficacy number medical device therapy patient chronic Heart failure reduce ejection fraction ( HFrEF ) , patient outcomes remain poor , especially hospitalization heart failure . The 1-year mortality rate HF hospitalization 20-30 % , number relatively unchanged past decade . These data suggest unmet need novel treatment strategy support assessment new approach post-acute HF setting . There also wide variation implementation clinical trial evidence routine practice . Previous data highlight multi-year gap generation new evidence clinical trial adoption data routine clinical practice . This gap care translate many unnecessary death hospitalization year patient HFrEF . While multiple reason quality gap , clinical inertia often note major barrier . Ivabradine approve use Europe several year patient symptomatic chronic HFrEF ( LVEF &lt; 35 % ) heart rate &gt; 75 bpm guideline-directed medical therapy ( intolerance/contra-indication beta-blocker use ) . Ivabradine recently approve use United States . However , US data exist regard potential adoption ivabradine routine clinical care . Previous data patient HFrEF suggest hospital setting may provide unique opportunity patient initiate guideline-directed medical therapy . In Initiation Management Predischarge : Process Assessment Carvedilol Therapy HF ( IMPACT-HF ) study , patient LVEF &lt; 40 % hospitalize HF start carvedilol prior hospital discharge likely beta-blocker 60 day post-randomization compare receive usual care . These improvement care achieve without increase side effect index hospitalization length stay . Similar beta-blockers medical therapy HF , ivabradine initially study patient chronic HF . The initiation ivabradine patient follow stabilization acute HF evaluate . • Design &amp; procedures The PRIME-HF study multi-center , patient-level , randomize , open-label study approximately 450 patient reduce LVEF &lt; 35 % heart-rate &gt; 70 bpm discharge hospital follow stabilization acute HF randomize treatment strategy predischarge initiation ivabradine usual care . All participant follow-up visit within 7-14 day hospital discharge . Heart rate systolic blood pressure assess clinical visit . For participant randomize predischarge initiation ivabradine ivabradine 5mg BID , heart rate may use adjust dose dose 2.5mg BID 7.5mg BID . For participant randomize usual care , ivabradine may initiate provider 's discretion . All participant second follow-up study visit 6 week ( 42 +/- 14 day ) post-discharge . Heart rate , systolic blood pressure quality life ( KCCQ PGA ) assess . For participant already take ivabradine either treatment group , heart rate may use adjust dose ivabradine . For participant yet receive ivabradine , may initiate provider 's discretion . All participant receive 90 ( +/-7 ) day post-discharge phone call site assess event status tolerability ivabradine . All participant final study visit 180 ( +/-14 ) day post-discharge . Heart rate , systolic blood pressure quality life ( KCCQ PGA ) assess . The attend physician may initiate ivabradine per usual care clinical practice .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Acute HF primary cause hospitalization define follow admission At least 1 HF symptom ( e.g. , dyspnea , orthopnea , peripheral edema ) At least 1 HF sign ( e.g. , rales auscultation , elevate jugular venous pressure [ JVP ] , ascites , pulmonary vascular congestion chest radiography ) Serum/plasma natriuretic peptide elevation index hospitalization ( NTproBNP &gt; 1000 pg/ml BNP &gt; 250 pg/ml ) 2 . A prior clinical diagnosis HF 3 . Most recent LVEF ≤ 35 % within 6 month randomization LVEF ≤ 25 % within 12 month randomization 4 . On optimal guidelinedirected medical therapy HFrEF ( previously deem intolerant ) determine clinician include ACEinhibitors angiotensin receptor antagonist neprilysin inhibition , aldosterone receptor antagonist , maximallytolerated dos betablockers Maximallytolerated dos betablockers define treat physician consider aspect current dose relative target dose use clinical trial , patient heart rate blood pressure , patient symptom Patients intolerance contraindication betablocker use eligible enrollment ( detail document case report form ) 5 . Age &gt; 18 year 6 . Willingness provide informed consent subject ( guardian legally authorize representative [ LAR ] ) 7 . On day plan randomization , participant : Must sinus rhythm rest heart rate &gt; 70 bpm measure 2 consecutive 12lead ECGs ( 10second rhythm strip ) separate 5 minute Must blood pressure &gt; 90/50 mm Hg 1 . Previous use ivabradine 2 . Planned/scheduled uptitration betablocker follow 4 week 3 . Permanent atrial fibrillation atrial flutter 4 . Patients recent atrial fibrillation flutter define either precipitate current HF hospitalization occur current HF hospitalization 5 . History untreated sick sinus syndrome , sinoatrial block , second third degree atrioventricular block 6 . Pacemaker atrial ventricular pacing ( except biventricular pace ) &gt; 40 % time 7 . Family history congenital long QT syndrome treat select QTprolonging product ( e.g. , sotalol ) 8 . History symptomatic sustain ( &gt; 30 second ) ventricular arrhythmia unless cardioverter/defibrillator implant 9 . Recent myocardial infarction ( &lt; 2 month prior screen ) [ troponin elevation secondary acute HF determine clinician exclusion ] 10 . Acute chronic severe liver disease evidence follow : encephalopathy , variceal bleeding , INR &gt; 1.7 absence anticoagulation treatment 11 . Creatinine clearance &lt; 15 mL/min within 48 hour screen due acute kidney injury resolve 12 . Planned mechanical circulatory support within 180 day 13 . Pregnant . Women childbearing potential use effective contraception . 14 . Medical condition likely lead poor noncardiac survival 180 day ( e.g. , cancer ) 15 . Inability comply plan study procedure 16 . If following medication need inclusion study : Nondihydropyridine calcium channel blocker ( e.g. , diltiazem verapamil ) Class I antiarrhythmics ( e.g. , quinidine , procainamide , lidocaine , phenytoin ) Strong inhibitor cytochrome P450 3A4 ( CYP3A4 ) , include macrolide antibiotic ( e.g. , clarithromycin , erythromycin ) , cyclosporine , antiretroviral drug ( e.g. , ritonavir , nelfinavir ) , systemic azole antifungal agent ( e.g. , ketoconazole , itraconazole ) . Inducers cytochrome P450 3A4 ( CYP3A4 ) include St. John 's wort . Treatments know associated significant prolongation QT interval , include sotalol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>